Parenteral Drug (India) announcements, page 8

Feb 2019

14 Feb · Board meeting
Meeting of the Board of Directors of the Company was held on Thursday, the 14th day of February, 2019 at 12.00 Noon at the Corporate Office of the Company at Indore and concluded at 05.40 .... (opens in a new tab)
14 Feb · Results
Financial results for the period ended December 31, 2018. (opens in a new tab)
14 Feb · Board meeting
Board meeting held on February 14, 2019 in which Board inter alia considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the third quarter of the financial year 2018-19 ended on 31st December, 2018. (opens in a new tab)
7 Feb · Board meeting
PARENTERAL DRUGS (INDIA) LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2019 ,inter alia, to consider and approve the Unaudited .... (opens in a new tab)
7 Feb · Board meeting
To consider and approve the financial results for the period ended December 31, 2018 and other business matters (opens in a new tab)

Jan 2019

22 Jan · Legal
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the .... (opens in a new tab)
22 Jan · Legal
Significant movement in price has been observed in Parenteral Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parenteral Drugs (India) Limited has submitted their response. (opens in a new tab)
The exchange asked on 21 Jan 2019
21 Jan · Legal
Exchange has sought clarification from Parenteral Drugs India Ltd on January 21, 2019 with reference to significant movement in price, in order to ensure that investors have latest ....
18 Jan · Shareholding for the Period Ended December 31, 2018
Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click ....
8 Jan · Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0

Dec 2018

Nov 2018

Oct 2018

24 Oct · Submission Of Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Please find attached herewith, the Compliance Certificate required to be submitted under Regulation 7(3) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 for .... (opens in a new tab)
24 Oct · Submission Of Compliance Certificate Pursuant To Regulation 40(10) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Please find attached herewith, Certificate as per Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 duly certified by M/s. Archna Maheshwari .... (opens in a new tab)
20 Oct · Shareholding for the Period Ended September 30, 2018
Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click ....
8 Oct · Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0

Sep 2018

Aug 2018

Jul 2018

19 Jul · Shareholding for the Period Ended June 30, 2018
Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click ....
11 Jul · Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
10 Jul · Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirement) Regulations, 2015 About Variation In The Percentage Of Shareholding Of The Company In Its Wholly Owned Subsidiary Company
Dear Sir This is for the information of the Exchange, its members and general public that pursuant to the right exercised by the one of the preference shareholders of the subsidiary .... (opens in a new tab)
10 Jul · Updates
This is for the information of the Exchange, its members and general public that pursuant to the right exercised by the one of the preference shareholders of the subsidiary company of the company viz. M/s Infutec Healthcare Limited, it has converted the preference shares into equity shares and resultantly the subsidiary has ceased to be the subsidiary of the company. (opens in a new tab)
10 Jul · Legal
Exchange had sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is enclosed. (opens in a new tab)
3 Jul · Legal
Exchange has sought clarification from Parenteral Drugs (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted -2. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.

Parenteral Drug (India) share news and announcements

Parenteral Drug (India) share news and announcements

Feb 2019

Jan 2019

Dec 2018

Nov 2018

Oct 2018

Sep 2018

Aug 2018

Jul 2018

Jun 2018